Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial

Additional readouts from Valneva SE's VALN pivotal VLA2001-301 "Cov-Compare" trial of COVID-19 vaccine VLA2001 showed persistent and first positive heterologous booster results following AstraZeneca Plc's AZN COVID-19 primary vaccination.
After two months, neutralizing antibody titers induced by VLA2001 was non-inferior to AstraZeneca's COVID shot (ChAdOx1-S).
GMT was 444.0, and ChAdOx1-S GMT was 411.8.
Related: Valneva Cuts FY22 COVID-19 Vaccine Sales Outlook, Needs Funding To Invest In Next-Gen COVID-19 Shot.
Seroconversion rates remained constant (above 92% in both treatment groups).
Additionally, approximately six months after primary vaccination showed that VLA2001 induced broad antigen-specific IFN-gamma-producing T-cells reactive against the S-protein and the N- and M-proteins.
The safety profile of VLA2001 continues to be favorable, and the vaccine was well tolerated.
The occurrence of COVID-19 cases was similar between the VLA2001 and ChAdOx1-S groups.
Neutralizing antibody titers following a VLA2001 booster dose administered approximately eight months after primary vaccination were between 3-fold (heterologous) to 28-fold (homologous) higher than pre-boost levels, in line with previous VLA2001 Phase 1/2 homologous booster results.
Price Action: VALN shares closed at $18.03 on Friday.